The Genome Sequencing Centers (GSCs) use high-throughput Sanger/di-deoxy technology to sequence gene and genomic target regions. Putative mutations in tumor genomes are verified to have a somatic origin by comparison to DNA sequence derived from normal tissue from the same patient. The result of these analyses will be identification of tumor mutations at single nucleotide resolution.
GBM gene lists:
- Click here for the integrated GBM target list for phases one and two.
- Click here for the phase one GBM gene list.
- Click here for the phase two GBM target list.
The targets for the TCGA genomic sequencing studies will consist of genes and candidate regions selected through the combination of two different approaches. In one approach, genes of interest (e.g., tumor repressors or oncogenes) are identified from the scientific literature and by consultation with experts in the field. The second approach, genes and genomic regions are identified by analyses of the data produced by the TCGA Cancer Genome Characterization Centers (CGCCs).
Genes Being Sequenced in Glioblastoma:
Approximately 600 genes were selected for the first round of glioblastoma multiforme
(GBM) tumor sequencing. To see the first GBM gene list, click here.
- This list of genes was generated through a cooperative process; for details about the process, click here. The process is unique to the selection of the initial GBM targets and may or may not reflect future processes for selecting targets.
From the characterization data generated as of October 22, 2007 as well as input from the GBM disease experts, approximately 700 targets were selected for the second round of GBM tumor sequencing. To read a brief description of the selection process, click here. To see the GBM target list for phase two, click here.
To see the integrated GBM target list for phases one and two, click here.
